David L. Szekeres

David L. Szekeres has more than two decades of experience in the global life sciences industry as a finance and business development executive, deal maker, legal counsel and Board member. Szekeres currently serves as executive vice president and chief operating officer of Heron Therapeutics, Prior to this, he served as chief business officer, principal financial officer and general counsel at Regulus Therapeutics Inc. Previous to this role, Szekeres served as head of Mergers and Acquisitions, Securities and Governance, at Life Technologies Corporation through its acquisition by Thermo Fisher Scientific. Prior to this position, Szekeres served as corporate attorney at a number of law firms, including Latham & Watkins LLP; and served as senior associate in Investment Banking at Robertson Stephens.

In addition to his role on Sanford Burnham Prebys’ Board, Szekeres serves as chair of the Board of Directors of Annai Systems, a genomic data solutions company; and chair of the Board of Directors of Animantis, LLC, a software company applying cloud-based artificial intelligence to drug discovery and development. He served on the Board of Directors of Edico Genome Inc. until its acquisition by Illumina, and Patara Pharma, until its acquisition by Roivant Sciences.

Szekeres obtained a J.D. degree from Duke University School of Law and a bachelor’s degree in criminology, law and society from the University of California, Irvine.